On Tuesday, CME Group Cl A received a positive adjustment to its Relative Strength (RS) Rating, from 88 to 92.
IBD's proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against other publicly traded companies.
Over 100 years of market history shows that the market's biggest winners tend to have an 80 or better RS Rating in the early stages of their moves.
How To Use Stock Charts To Stay Profitable And Protected
CME Group Cl A is still inside a buy zone after moving past a 249.02 buy point in a cup without handle. Once a stock moves 5% or higher beyond the initial entry, it's considered extended and out of buy range.
The company showed 6% earnings growth last quarter. Sales increased 6%.
The company holds the No. 6 rank among its peers in the Financial Services-Specialty industry group. Tiptree, Tradeweb Markets and X Financial ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
